Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

Precision and Future Medicine is an esteemed academic journal published by Sungkyunkwan University School of Medicine, dedicated to advancing the fields of precision medicine and healthcare innovation. Established as an Open Access journal in 2017, it aims to disseminate cutting-edge research and insights that bridge the gap between basic and clinical sciences. With a focus on personalized medicine, genomics, and advanced therapeutic strategies, the journal serves as a vital resource for researchers, clinicians, and policy makers. Set in the dynamic environment of South Korea, Precision and Future Medicine provides a platform for the exchange of ideas that are shaping the future of medical science, thus contributing significantly to the global dialogue on health and wellness. As it continues to grow, the journal is committed to ensuring that high-quality research remains accessible to all, fostering a spirit of collaboration and innovation within the scientific community.

ANNALES DE BIOLOGIE CLINIQUE is a prominent French journal dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Immunology, and Microbiology. Published by JOHN LIBBEY EUROTEXT LTD, this journal has been a pivotal resource since its inception in 1945, offering a rich archive of original research, reviews, and clinical studies that aim to bridge the gap between laboratory findings and clinical applications. Despite its ranking in the Q4 quartile within several scientific categories according to the 2023 Scopus rankings—positioning it at #395/636 in General Medicine and #198/221 in General Biochemistry—ANNALES DE BIOLOGIE CLINIQUE serves as a vital platform for emerging researchers and seasoned professionals alike, fostering collaboration and innovation in these vital areas of health science. As an essential tool for researchers and scholars, the journal does not currently provide open access; however, it continuously strives to enhance its impact and visibility in the scientific community through rigorous peer-reviewed content and educational contributions.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

JOURNAL OF BIOMEDICAL SCIENCE, published by BMC, is a premier Open Access journal dedicated to the rapid dissemination of research in the fields of biomedical science, encompassing crucial areas such as biochemistry, cell biology, clinical biochemistry, and more. Since its inception in 1993, the journal has established itself as a leading publication, currently boasting a remarkable impact factor and quality as evidenced by its Q1 quartile rankings across multiple categories in 2023. With an impressive track record, including a Scopus ranking in the top percentiles across several disciplines, it serves as a vital resource for researchers, professionals, and students who are keen on advancing their knowledge in biomedicine. The journal operates under a fully Open Access model, ensuring that all published articles are freely available to the global research community, thus contributing to the broader dissemination and accessibility of scientific knowledge. Based in the United Kingdom, JOURNAL OF BIOMEDICAL SCIENCE is committed to fostering innovation and collaboration in research, appealing to those aiming to make impactful contributions to the biomedical sphere.

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.

The Journal of Pathology Clinical Research is a prestigious academic platform published by WILEY, dedicated to advancing the field of pathology and forensic medicine. Since its inception in 2015, this Open Access journal has championed the dissemination of cutting-edge research relevant to both clinical practice and laboratory science, allowing for greater visibility and accessibility to researchers, professionals, and students worldwide. With a robust Q1 ranking in the Pathology and Forensic Medicine category for 2023, it stands as a critical resource for those seeking to stay at the forefront of the field, currently positioned at rank #29 out of 208 according to Scopus metrics, placing it in the 86th percentile. The journal's commitment to high-quality peer-reviewed articles fosters an environment of scholarly exchange that is essential for innovation and professional growth in pathology and forensic studies. Researchers and practitioners alike are encouraged to contribute and engage with a community dedicated to excellence in clinical research.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.